TrialGynecologic oncology2022

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Beryl L Manning-Geist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.